SUMMARY
Tyler S. Oesterle, M.D., M.P.H., is division chair of Addiction Services at Mayo Clinic's campus in Rochester, Minnesota, where he also serves as the medical director of residential and outpatient programs. Dr. Oesterle is the primary investigator for an opioid and multiple addiction biobank. Dr. Oesterle primarily focuses on research related to the diagnosis and treatment of substance use disorders, with a particular interest in opioid and stimulant use disorders.
Focus areas
- The science of better substance use disorder care delivery. Dr. Oesterle is researching the feasibility, acceptability and efficacy of virtual substance use disorder interventions in health care settings that typically lack access to these services, such as emergency departments, primary care and specialty clinics without dedicated mental health departments.
- Opioid and multiple addictions biobank (OMA). In collaboration with Brandon J. Coombes, Ph.D., Victor M. Karpyak, M.D., Ph.D., Richard Weinshilboum, M.D., and Ming-Fen Ho, Ph.D., Dr. Oesterle works to develop a comprehensive biological and digital repository of information on patients with substance use disorders.
- Senyo Health. In collaboration with Scott A. Breitinger, M.D., from the Division of Integrated Behavioral Health, Dr. Oesterle is researching a novel digital therapeutic application designed to improve substance use disorder treatment outcomes.
- Novel interventions to treat substance use disorders. Dr. Oesterle collaborates with Mayo Clinic colleagues to research new treatment modalities for substance use disorders. Current projects include exploring novel therapeutics to treat cocaine use disorder and researching the use of brain stimulation in treatment-resistant addiction.
Significance to patient care
As a clinician-researcher with a robust clinical practice, Dr. Oesterle researches interventions with real-world value to current patients. His research aims to combine digital and biological data with digital tools to allow optimal substance use disorder care where and when needed. Dr. Oesterle is pursuing a better understanding of the interplay between genetics, environment, mental health and substance use disorders through Mayo Clinic's OMA biobank. He also is interested in using technology such as neuromodulation, wearable devices and mobile phone applications to improve prevention, diagnosis and treatment for patients with substance use disorders. His app-based research platform called Senyo Health can improve digital interventions for patients with substance use disorders.